Prognostic impact of telomere maintenance gene polymorphisms on hepatocellular carcinoma patients with chronic hepatitis B

Hepatology

Volumn 59, Issue 5, 2014, Pages 1912-1920

  Jung, Seok Won ^a   Park, Neung Hwa ^a   Shin, Jung Woo ^a   Park, Bo Ryung ^a   Kim, Chang Jae ^a   Lee, Jong Eun ^b   Shin, Eun Soon ^b   Kim, Jeong A ^a   Chung, Young Hwa ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b DNA Link Inc   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; FEMALE; GENOTYPE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TELOMERE; TELOMERE-BINDING PROTEINS;

EID: 84899481080     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26655     Document Type: Article

References (41)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
2. Kim SE, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean J Hepatol 2011;17:113-119.
3. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15(suppl):E25-E30.
4. Yu MW, Yang SY, Pan IJ, Lin CL, Liu CJ, Liaw YF, et al. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2003;95:1485-1488.
5. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005;11:289-292.
6. Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology 2005;48:10-15.
7. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010;42:755-758.
8. Li S, Qian J, Yang Y, Zhao W, Dai J, Bei JX, et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 2012;8:e1002791.
9. Meeker AK, Argani P. Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation? J Mammary Gland Biol Neoplasia 2004;9:285-296.
10. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-573.
11. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005;6:611-622.
12. Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med 2006;147:58-66.
13. Farazi PA, Glickman J, Jiang S, Yu A, Rudolph KL, DePinho RA. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003;63:5021-5027.
14. Shen J, Gammon MD, Wu HC, Terry MB, Wang Q, Bradshaw PT, et al. Multiple genetic variants in telomere pathway genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2010;19:219-228.
15. Catarino R, Araujo A, Coelho A, Gomes M, Nogueira A, Lopes C, et al. Prognostic significance of telomerase polymorphism in non-small cell lung cancer. Clin Cancer Res 2010;16:3706-3712.
16. Nan H, Qureshi AA, Prescott J, De Vivo I, Han J. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet 2011;129:247-253.
17. Jones AM, Beggs AD, Carvajal-Carmona L, Farrington S, Tenesa A, Walker M, et al. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut 2012;61:248-254.
18. Prescott J, McGrath M, Lee IM, Buring JE, De Vivo I. Telomere length and genetic analyses in population-based studies of endometrial cancer risk. Cancer 2010;116:4275-4282.
19. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
20. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74.
21. Baykal A, Rosen D, Zhou C, Liu J, Sahin AA. Telomerase in breast cancer: a critical evaluation. Adv Anat Pathol 2004;11:262-268.
22. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442.
23. Savage SA, Stewart BJ, Eckert A, Kiley M, Liao JS, Chanock SJ. Genetic variation, nucleotide diversity, and linkage disequilibrium in seven telomere stability genes suggest that these genes may be under constraint. Hum Mutat 2005;26:343-350.
24. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-1223.
25. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
26. Bell PA, Chaturvedi S, Gelfand CA, Huang CY, Kochersperger M, Kopla R, et al. SNPstream® UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques 2002;32(suppl):S70-S77.
27. Denomme GA, Van Oene M. High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes. Transfusion 2005;45:660-666.
28. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002;30:e47.
29. Yokota T, Suda T, Igarashi M, Kuroiwa T, Waguri N, Kawai H, et al. Telomere length variation and maintenance in hepatocarcinogenesis. Cancer 2003;98:110-118.
30. Plentz RR, Caselitz M, Bleck JS, Gebel M, Flemming P, Kubicka S, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 2004;40:80-86.
31. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstatter A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA 2010;304:69-75.
32. Baumann P, Cech TR. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 2001;292:1171-1175.
33. Kelleher C, Kurth I, Lingner J. Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro. Mol Cell Biol 2005;25:808-818.
34. Lei M, Zaug AJ, Podell ER, Cech TR. Switching human telomerase on and off with hPOT1 protein in vitro. J Biol Chem 2005;280:20449-20456.
35. Savage SA, Chanock SJ, Lissowska J, Brinton LA, Richesson D, Peplonska B, et al. Genetic variation in five genes important in telomere biology and risk for breast cancer. Br J Cancer 2007;97:832-836.
36. Hosgood HD III, Menashe I, Shen M, Yeager M, Yuenger J, Rajaraman P, et al. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 2008;29:1938-1943.
37. Ducrest AL, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002;21:541-552.
38. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-959.
39. Hsu CP, Hsu NY, Lee LW, Ko JL. Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter-effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 2006;42:1466-1474.
40. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 2008;42:301-334.
41. Choi JE, Kang HG, Jang JS, Choi YY, Kim MJ, Kim JS, et al. Polymorphisms in telomere maintenance genes and risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2773-2781.